| 000 | 00878 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250517100209.0 | ||
| 264 | 0 | _c20171106 | |
| 008 | 201711s 0 0 eng d | ||
| 022 | _a1098-4275 | ||
| 024 | 7 |
_a10.1542/peds.2016-0057 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aQuinn, Graham E | |
| 245 | 0 | 0 |
_aConcerns for Development After Bevacizumab Treatment of ROP. _h[electronic resource] |
| 260 |
_bPediatrics _c04 2016 |
||
| 500 | _aPublication Type: Journal Article; Comment | ||
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 | _aGestational Age |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIntravitreal Injections |
| 650 | 0 | 4 | _aRetinopathy of Prematurity |
| 700 | 1 | _aDarlow, Brian A | |
| 773 | 0 |
_tPediatrics _gvol. 137 _gno. 4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1542/peds.2016-0057 _zAvailable from publisher's website |
| 999 |
_c26076167 _d26076167 |
||